Patient Engagement
Apple on Monday unwrapped the CareKit and described the new software as a framework for building apps that can empower people take a more active role in their own care.
California's insurance exchange is threatening to cut hospitals from its networks for poor performance or high costs, a novel proposal that is drawing heavy fire from medical providers and insurers.
More consumers across all demographics are using alternative sites of care, including retail health clinics, urgent care centers and telehealth, according to a new online survey by management consulting firm Oliver Wyman. And many of those consumers are having good experiences.
Medical groups have already started educating their members about the law and other end-of-life options. The California Medical Association issued a document earlier this year that explains to doctors and patients how the law works. Many physicians are going to have to figure out how to talk to patients when the patients raise the question.
A recent American Journal of Managed Care study has confirmed prices for care in a hospital outpatient department tend to be higher than those for the same service performed in a physician's office.
Across the country, more than 50 rural hospitals have closed over the last six years, and another 283 are in fragile financial condition, according to the National Rural Health Association.
Two states are making inroads into revealing some of the biggest secrets of health care by publishing price information to help consumers comparison shop for doctors, dentists and prescription drugs.
Retail clinics, long seen as an antidote to more expensive doctor offices and emergency rooms, may actually boost medical spending by leading consumers to get more care, a new study shows.
Most of the people running for president say they want to do something about the rising cost of prescription drugs. But most of their proposals probably won't work because they don't address the dynamics behind these price increases.
MIT Sloan Professor Andrew Lo, Dana-Farber Cancer Institute's David Weinstock, and MIT post-doctoral fellow Vahid Montazerhodjat have identified this as a time when breakthrough therapies for certain types of cancers, hepatitis C, and rare diseases exist but remain out of reach for many patients, due primarily to the prohibitive cost.